Awọn ọja

Niacin (nicotinic acid) bi monotherapy le dinku eewu arun ti iṣan, ṣugbọn ilana iṣe rẹ jẹ ariyanjiyan, ati pe o le ma dale lori awọn ipa iyipada lipid eto eto.Niacin ti han laipẹ lati mu ilọsiwaju iṣẹ endothelial ati isọdọtun ti iṣan, ominira lati ṣe atunṣe dyslipidemia, ni awọn awoṣe rodent ti ipalara iṣan ati arun ti iṣelọpọ.Gẹgẹbi iṣaju biosynthetic ti o pọju fun NAD (+), niacin le fa awọn anfani iṣan wọnyi jade nipasẹ NAD (+) -igbẹkẹle, awọn idahun sirtuin (SIRT).Ni omiiran, niacin le ṣiṣẹ nipasẹ olugba rẹ, GPR109A, lati ṣe igbelaruge iṣẹ endothelial, botilẹjẹpe awọn sẹẹli endothelial ko mọ lati ṣafihan olugba yii.A ṣe akiyesi pe niacin taara ṣe ilọsiwaju iṣẹ sẹẹli endothelial lakoko ifihan si awọn ipo lipotoxic ati pe o wa lati pinnu ilana ti o pọju ninu palmitate. ifọkansi kekere ti niacin (10 μM), tabi nicotinamide mononucleotide (NMN) (1 μM), iṣaju NAD (+) taara kan.Botilẹjẹpe mejeeji niacin ati NMN ni ilọsiwaju iṣelọpọ tube HMVEC lakoko apọju palmitate, NMN nikan ni o pọ si NAD (+) cellular ati iṣẹ SIRT1.A tun ṣe akiyesi pe HMVEC ṣafihan GRP109A.Iṣiṣẹ ti olugba yii pẹlu boya acifran tabi MK-1903 tun ṣe awọn ilọsiwaju niacin-induced ni dida HMVEC tube, lakoko ti GPR109A siRNA dinku ipa ti niacin.Niacin, ni ifọkansi kekere, ṣe ilọsiwaju iṣẹ angiogenic HMVEC labẹ awọn ipo lipotoxic, o ṣeeṣe ominira ti NAD ( +) biosynthesis ati imuṣiṣẹ SIRT1, ṣugbọn dipo nipasẹ imuṣiṣẹ olugba niacin.